-
Merca East Head-to-Head Phase 3 Study: Adding Yeervoy to Keytruda benefits does not increase toxicity
Time of Update: 2021-03-12
the study was conducted in patients with metastasis non-small cell lung cancer (NSCLC) without EGFR or ALC genomic tumor distortion, tumor expression PD-L1 (tumor ratio score (TPS) ≥50%) and evaluated the efficacy and safety of Keytruda and Yervoy (ipilimumab, Iplimma) immunocommunication therapy, and Keytruda monotherapy for first-line therapy.
-
AstraZeneta Tagrisso assists in the treatment of early EGFR mutation lung cancer: prolonging disease-free survival
Time of Update: 2021-03-12
data show that tagrisso-assisted therapy significantly prolongs disease-free survival (DFS) in patients with EGFRm non-small cell lung cancer (NSCLC), regardless of whether they have previously received complementary chemotherapy treatment or disease stage.
-
Once a week under the skin injection growth hormone! Noor and Nord Sogroya are recommended by THECHMP
Time of Update: 2021-03-12
Novo Nordisk recently announced that the European Medicines Agency's (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending the approval of the weekly long-acting growth hormone derivative Sogroya (somapacitan-beco) for the treatment of adult growth hormone deficiency (AGHD).
-
Huaxi bio-hyalurino acid sodium has been approved for use in common foods
Time of Update: 2021-03-12
2004, Huaxi Bio began to promote the expansion of the scope of application of sodium hyalurino acid, the year declared sodium hyalurogenate as a new resource food, and was approved in 2008, but the scope of application is limited to health food raw materials.
-
There is no need for complementary chemotherapy oghithinib to prolong the disease-free survival of patients with early EGFR mutation lung cancer
Time of Update: 2021-03-12
The trade name Tagrisso prolongs disease-free survival (DFS) in patients with EGFRm non-small cell lung cancer (NSCLC), independent of previous complementary chemotherapy treatments or disease stages.
as the pre-defined exploratory analysis shows, Oghithini-assisted therapy led to clinically significant improvements in DFS in CNS patients compared to placebos.
-
470 million! Kyusju Tong has another big move
Time of Update: 2021-03-12
with increased investment in pharmaceutical research and development, the biopharmaceutical market is expected to reach RMB1,319.8 billion in 2030, with a compound annual growth rate of 10.9% from 2023 to 2030.
-
Sudden! A pharmaceutical company issued an announcement full of home office
Time of Update: 2021-03-12
the | Kathy burst! Jilin a pharmaceutical company issued an announcement, because the area was adjusted to a high-risk area, all employees at home office pharmaceutical company issued an announcement
-
Koren Pharmaceuticals: Sodium fluconazole sodium chloride injections, etc. are evaluated consistently
Time of Update: 2021-03-12
at the same time, also issued a notice of approval, the company recently obtained the Approval Notice of the Chemical Drug "Fat Milk (10%)/Amino Acids (15)/Glucose (20%) Injection" approved by the State Drug Administration, which is evaluated by the quality and efficacy of generic drugs.
-
Jansen EGFR/MET dual-specific antibodies had positive results in the treatment of specific non-small cell lung cancer
Time of Update: 2021-03-12
Janssen, a unit of Johnson and Johnson, has released the latest results for its dual-specific antibody amivantamab, which is used to treat patients with metastasis or inexorable small cell lung cancer (NSCLC) inserted in the treatment of exosome 20 that carries a dermis growth factor (EGFR).
-
Huaxi Bio appointed Gao Yi as deputy general manager
Time of Update: 2021-03-11
On February 19, Huaxi Bio announced that the company held the 20th meeting of the first board of directors, considered and passed the "On the appointment of senior managers of the company", agreed to
-
Far exceeding the industry average year-on-year net profit growth of 340.5% Haizheng how to attract high capital
Time of Update: 2021-03-11
Among them, Haizheng Pharmaceuticals with annual net profit of 410 million yuan, an increase of 340.5% YoY excellent data, significantly ahead of the industry average, ranked 17th in the overall industry, you know this is included in the outbreak during the surge in revenue masks, testing reagents and other equipment industry, if the interference factors are excluded, Haizheng Pharmaceuticals last year's performance properly into the top 5.
-
The world's first chemotherapy bone marrow protection preventive therapy has been approved! First Sound Pharmaceuticals has Chinese interests
Time of Update: 2021-03-11
On February 13, 2021, Beijing time, G1 Therapeutics announced that its main product, Trilaciclib (trade name: COSELA), has been approved by the FDA to prevent bone marrow inhibition in adult patients with diffused stage small cell lung cancer due to the platinum-based etoposide solution or topological tetosine therapy.
-
AZ 2020 Results: The anti-tumor business is growing rapidly with Enhertu's first year of sales of $200 million
Time of Update: 2021-03-11
Olapali and Acatini are also fast-growing varieties in the oncology business, and the future of both varieties is still noteworthy: the progress of the Olapali, Paboliju monoantigenic joint programme, of which the first-line maintenance treatment of advanced non-small cell lung cancer is of particular concern; Acatinib has been approved for first-line treatment of chronic lymphatic leukemia, while Acatini vs.
-
Cold thinking: What exactly is barquoonase API?
Time of Update: 2021-03-11
The original research party for the product "Baquase Injection" was Tobishi Pharm of Japan, and the adaptation was "chronic arterial astrology, improvement of terminal circulatory disorders of vibration disease, recovery of sudden deafness, and improvement of conscious symptoms" and was not used in the treatment of cerebral infarction (ischemic stroke).
-
JAK inhibitors: a target favored by major pharmaceutical companies at home and abroad, domestic track Hengrui leading
Time of Update: 2021-03-11
unlike first-generation products, second-generation JAK inhibitors selectively inhibit members of the JAK family, enabling other cytokine functions to remain unaffected while suppressing specific disease-related signaling path path paths.
-
Several vaccine companies in the COVID-19 outbreak rejoiced
Time of Update: 2021-03-11
Pfizer expects to sell $15 billion of COVID-19 vaccines with BioNTech in 2021.
GSK expects sales in the sector to be flat or maintain low single-digit growth in 2021 if vaccination rates pick up in the second half of the year.
-
China Resources Double Crane / Long Chain Fat Emulsion (C8-24)) was approved for production
Time of Update: 2021-03-11
was developed by the German company Belang and approved for listing in Europe in 1990 under the name "Lipofundina MCT/LCT", which was licensed for import and marketed in China in 2001 and has been listed and sold in dozens of countries around the world, including China, Europe, Russia, Saudi Arabia and Indonesia.
-
The latest appointment for Pfizer's oncology business
Time of Update: 2021-03-11
Oncology Business Group 2 Colleagues will report directly to Mr. Yue Jie, Sales Director of Pfizer Biopharmaceutical Group China Group II: Mr. Tian Xiaojia, Senior Medical Information Communication Regional Manager, Cancer Business Group II North District, Beijing.
-
TOP3 hemostotting drug injections are selling out to shock the first review
Time of Update: 2021-03-09
Figure 1: Chengdu Ptot Pharmaceuticals' ammonia cyclic acid injection registration source: CDE official website Figure 2: Sales of amino acid Source: Minet China's public medical institutions terminal competition pattern ammonia cyclic acid is a classic anti-hematology drug, currently in the surgical trauma of artificial joint replacement is an essential perioperative drug.
-
Amjin's layoff sales team expands its business layout in the Chinese market
Time of Update: 2021-02-24
Reportedly, the California-based drugmaker confirmed Wednesday that it will cut jobs in the future, mainly in the U.S., as amser plans to shift its focus to upcoming drug and product lines and adopt digital marketing tools for the new crown outbreak.
